By Pharma Packaging Offers A Roadmap
Medical cannabis companies developing new products or redesigning packaging are being advised to look beyond current cannabis requirements and study pharmaceutical packaging standards.
Pharmaceutical packaging has spent decades addressing child resistance, tamper evidence, and product traceability, the same issues medical cannabis companies face today.
Germany’s medical cannabis market already operates under pharmaceutical manufacturing and distribution requirements, while Australia’s Therapeutic Goods Administration regulates medicinal cannabis within its therapeutic-goods framework.
In the U.S., cannabis packaging requirements remain largely state-based, but companies are making packaging decisions that could stay in place for years.
Changing a package later can mean new tooling, stability testing, supplier qualification, artwork and labeling changes, along with additional cost.
Child Resistance Standards
Child-resistant packaging in the U.S. is governed by a federal law that predates the modern cannabis industry by half a century.
The Poison Prevention Packaging Act gave the Consumer Product Safety Commission authority to require special packaging for hazardous household substances.
Aspirin was the first drug required to ship in child-resistant packaging in 1972, followed by iron-containing products in 1978, acetaminophen in 1980, diphenhydramine in 1984, and ibuprofen in 1992.
Cannabis packaging has developed along a similar path, with a documented shift away from bulky exit bags toward child-resistant mechanisms built into primary packaging, including push-and-turn caps, slide-lock tins, and heat-sealed pouches.
Tamper Evidence And Production Planning
Modern tamper-evident drug packaging emerged from the 1982 Tylenol poisonings, when someone placed cyanide in Tylenol capsules that had reached retail shelves in the Chicago area, killing seven people.
Congress followed in 1983 with the Federal Anti-Tampering Act, making product tampering a federal crime.
Australia’s TGA applies therapeutic-goods packaging requirements to medicinal cannabis products, including requirements intended to protect products from contamination and degradation.
Tamper evidence can affect the package itself and the manufacturing process, so evaluating seals, closures, and films during R&D gives companies more flexibility than adding those features after commercial production begins.
